News for Cellebrite DI Ltd. (CLBT)

JPMorgan has adjusted its price target for Cellebrite (CLBT), reducing it from $22 to $20. Despite the downgrade, the firm maintains an Overweight rating on the

On June 6, 2025, Needham analyst Mike Cikos reaffirmed a Buy rating for Cellebrite DI (CLBT). The financial advisory firm maintained its price target for the co

Cellebrite DI Ltd. (NASDAQ:CLBT) makes a move to acquire Corellium, a developer of Arm-based virtualization software. The transaction is valued at $170 million in cash, plus up to $30 million in contingent consideration, and reflects the company’s deepening footprint across the mobile security and digital intelligence spectrum. The acquisition of Corellium introduces mobile vulnerability research […]

Cellebrite DI Ltd. (NASDAQ:CLBT) makes a move to acquire Corellium, a developer of Arm-based virtualization software.

Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump’s Liberation Day […]

Operator: Welcome to the Cellebrite First Quarter 2025 Financial Results Conference Call.

ARR Growth: 23% year-on-year increase to $408 million.Adjusted EBITDA Growth: 34% year-on-year growth, resulting in a 22% margin.Revenue: $107.5 million, a 20%

May 14, 2025 / 12:30PM GMTOperator Welcome to the Cellebrite first quarter 2025 financial results conference call. At this time, all participants have been plac

On May 14, 2025, Needham analyst Mike Cikos maintained a "Buy" rating for Cellebrite DI (CLBT) despite lowering the price target. The price target was adjusted

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.08% to 42,172.43 whi...

Based on the information gathered, I'll now write the requested article about today's midday market update.

Cellebrite DI Ltd. (CLBT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

On December 31, 2024, Greenhaven Road Investment Management, L.P. (Trades, Portfolio) executed a significant transaction involving Lifecore Biomedical Inc. The

Shares of Cellebrite DI Ltd (CLBT) fell 5.30% in mid-day trading on Feb 14. The stock reached an intraday low of $20.35, before recovering slightly to $20.55,

Cellebrite DI Ltd. (NASDAQ:CLBT) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsAndrew Kramer - IRTom Hogan - Interim...

The following slide deck was published by Cellebrite DI Ltd.

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Cellebrite DI Ltd (CLBT), a leader in digital investigative solutions, announced its financial results for the fourth quarter and full year ending December 31,

Company delivers ”œRule of 50” Performance in 2024 with 25% ARR growth and 25% adjusted EBITDA margin Fourth-quarter 2024 revenue of $109.0 million grew 17%